Supplementary Figure 2 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
Laetitia E. Lamberts(University Medical Center Groningen), Gooitzen M. van Dam(Polpharma Biologics (Netherlands)), Annelies Jorritsma‐Smit(The Netherlands Cancer Institute), Wouter B. Nagengast(University Medical Center Groningen), Matthijs D. Linssen(The Netherlands Cancer Institute), Liesbeth Jansen(Dialyse Centrum Groningen), P. J. van Diest(University Medical Center Utrecht), Jürgen Glatz(Helmholtz Munich), Arjen J. Witkamp(University Medical Center Utrecht), Mariëtte E.G. Kranendonk(Princess Máxima Center), Willem P.Th.M. Mali(Utrecht University), Vasilis Ntziachristos(Helmholtz Zentrum München), Elisabeth G.E. de Vries(Karolinska University Hospital), Esther de Boer(University Medical Center Groningen), Sjoerd G. Elias(Utrecht University), Elsken van der Wall(University Medical Center Utrecht), Maximillian Koch(Helmholtz Munich), Johannes S. de Jong(Utrecht University), Carolien P. Schröder(University Medical Center Groningen), Anton G.T. Terwisscha van Scheltinga(University Medical Center Groningen), Marjolijn N. Lub–de Hooge(University Medical Center Groningen), Arthur L.L. Adams(Utrecht University), Jakob de Vries(Tilburg University), Sabrina Oliveira(Unknown), Bert van der Vegt(University Medical Center Groningen)
Cited by 0
Related Papers
Shedding light onto live molecular targets
|Nature Medicine|2003|1.9k
Looking and listening to light: the evolution of whole-body photonic imaging
|Nature Biotechnology|2005|1.6k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging
|European Radiology|2003|978
Fluorescence molecular tomography resolves protease activity in vivo
|Nature Medicine|2002|825